Statins Don't Increase Risk of Colchicine Myopathy Save
Neuromyopathy is a rare side effect of chronic colchicine use. Statins are more commonly implicated as a cause of drug-induced myopathy.
Given the frequent occurrence of the metabolic syndrome, simultaneous use of both colchicine and statins is common.
A Korean study compared 486 gout patients on colchicine against 188 on colchicine and a statin.
The incidence of myopathy was not significantly higher in those on both drugs than in those on colchicine alone (2.7% vs 1.4%, p = 0.330).
Risk factors for myopathy included chronic kidney disease (HR 29.1; 95% CI 4.38–192.4), liver cirrhosis (HR 10.7), higher colchicine doses (HR 21) and concomitant CYP 3A4 inhibitor use (HR 12.0).
Concomitant use of statins did not increase the use of myopathy (HR 1.1; 95% CI 0.262–4.814) in gout patients on colchicine.